Lindmik research | frontier information of drug delivery technology (6)
Click:359  Update time:2022-07-25  【Close

The world's only transdermal nonsteroidal anti-inflammatory drug for cancer pain—ZICTHORU Tapes 75mg

On May 21, 2021, diclofenac sodium transdermal preparation was supplied to the market in Japan for the treatment of persistent cancer pain (trade name: 75mg). The product was approved for production and sale on March 23, and was listed in the price list of national health insurance of Japan on May 19. The indication is "pain relief of various cancers", and the dose is "adults usually once a day, 2 patches (150 mg) for the chest, abdomen, upper arm, back, lower back or thigh. It is replaced every 24 hours. According to the symptoms and conditions, the dose can be increased to 3 patches (225 mg) per day."

ZICTHORU Tapes 75mg Physical picture

Source: Japan Jiuguang official website

With the progression of cancer, the frequency of cancer pain increases, which will not only cause physical pain, but also have psychological and social effects, thus significantly reducing the quality of life and daily activities of patients. According to Japanese and international pain management guidelines, the drug treatment of cancer pain should be selected according to the degree of pain of patients. Patients should use non opioid analgesics, such as non steroidal anti-inflammatory drugs (NSAIDs) or paracetamol, or opioid analgesics, which should be used alone or in combination according to the condition. Among them, the combination of non steroidal anti-inflammatory drugs and opioid analgesics is also expected to produce additive or synergistic analgesic effects. However, in Japan, among the non opioid analgesics including non steroidal anti-inflammatory drugs, the preparations that can be used for cancer pain are limited to oral and injection drugs.

Diclofenac sodium is a non steroidal anti-inflammatory drug based on phenylacetic acid, which shows analgesic and anti-inflammatory effects by inhibiting cyclooxygenase (COX). Compared with other non steroidal anti-inflammatory drugs, diclofenac sodium has higher COX-2 inhibitory activity, mainly inducing expression in inflammatory sites. In Japan, tablets, sustained-release capsules, suppositories, eye drops, gel, enemas, tapes, patches, lotions and creams have been widely used in various clinical departments.

ジクトルテープ/ ZICTHORUIt is a transdermal preparation of diclofenac sodium and the first transdermal nonsteroidal anti-inflammatory drug used to treat persistent cancer pain in the world. Once a day, it is expected to maintain a stable plasma drug concentration for 24 hours and continuously inhibit cancer pain. The product is expected to be used in cancer pain patients who have nausea, vomiting, dysphagia, gastrointestinal obstruction, etc. related to the treatment of basic diseases or anticancer drugs and are difficult to take oral drugs.

ジクトルテープ/ ZICTHORUIts efficacy and safety were confirmed in two phase III clinical trials (randomized, placebo-controlled, double-blind, controlled trials and open label long-term drug administration studies) for cancer pain patients completed in Japan.
Side effects include itching at the application site (5% or more), erythema at the application site, epigastric pain, elevated ast, ALT and creatinine (all lower than 1-5%). Significant side effects include shock, anaphylaxis, gastrointestinal ulcer with hemorrhagic shock or perforation, gastrointestinal stenosis / obstruction, aplastic anemia, hemolytic anemia, agranulocytosis, thrombocytopenia and toxic epidermal necrolysis, Johnson syndrome, erythema (exfoliative dermatitis), acute kidney disease (interstitial nephritis, renal papillary necrolysis, etc.), nephrotic syndrome It may lead to asthma attack (aspirin asthma), interstitial pneumonia, congestive heart failure, myocardial infarction, aseptic epidermal nephritis, severe liver dysfunction, acute encephalopathy, rhabdomyolysis, cerebrovascular disease, etc.

Please pay attention to the following points when using drugs:

[figure 1, product DA]

Source: Social Network

"Attached figure 2, science and Technology Commission site"

Source: Social Network


Last:Lindmik research | new trends in the global dermatological drug market
Next:The application for listing of the first product flurbiprofen gel paste was accepted, and the development of Leming pharmaceutical entered a fast lane


Lindmik Pharmaceutical(Suzhou)Co.,Ltd is a high-tech pharmaceutical enterprise focusing on the research and development, production and sales of innovative pharmaceutical preparations.Equipped with a number of its own innovative R&D platform of dosage forms, including the transdermal drug delivery system, and at the same time, actively introducing the world’s leading nano-based drug delivery, microspheres drug delivery and other cutting-edge pharmaceutical technologies by means of “license in”, the company is a new rapidly developing company pharmaceutical companies that catches people’s eyes.




  • 12th Floor, Building 5, Tianyun Plaza, 111 Wusongjiang Avenue, Guoxiang Street, Wuzhong District, Suzhou City

  • 0512-66020899

  • 0512-66022699

  • 215124

© COPYRIGHT Lindmik Pharmaceutical(Suzhou)Co.,Ltd. All Rights Reserved